58th IDMA Annual Day Celebrations 2020: A Report

IDMA celebrated its 58th Annual Day on Saturday, 18th January 2020 at Hotel St Regis, Mumbai. Earlier in the day, the 58th IDMA Annual General Meeting was held with the active presence of a large number of Members.

The Annual Day was graced by Chief Guest Hon'ble Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, Guests of Honour, Dr Mandeep K Bhandari, IAS Joint Secretary, Ministry of Health & Family Welfare and Dr V G Somani, Drugs Controller General (India) and the cream of Indian Pharma Leaders gathered together at this memorable event which had a presence of 350+people.

Mr Daara B Patel, Secretary-General, IDMA welcoming the august gathering said that "IDMA, as the premier National Association is now in its 58th year. We are 1000 plus Members strong and still growing." He also shared the theme for the year 'Indian APIs



& Pharmaceuticals for Global Healthcare'. He informed that IDMA has been bestowed with the first ever Indian Pharma Swachhta Champion Award 2019. (Excerpts from Shri Daara Patel's welcome address is published in the following pages):



National President Shri Deepnath Roy Chowdhury in his Presidential Address stated that "IDMA is respected by the Authorities & Policy makers because of our knowledge and credibility". (Excerpts from the Presidential address is published in

the following pages):

Incoming National President, Mr Mahesh H Doshi in his address said that he was "grateful to all our Past Presidents, Seniors and Members of the Executive Committee of IDMA for having bestowed confidence in me by



electing me as the first-ever Senior Vice-President of this great Association." (Excerpts from Shri Mahesh Doshi's address is published in the following pages):



Guest of Honour Dr V G Somani, Drugs Controller General (India), in his address said that our real area of focus is access to quality, affordable medicine. (*Excerpts from his speech*): "The three words are very important -Accessibility, Affordability and Quality. Our vaccines and medicines are going

to 195 countries which are great achievements. As far as quality is concerned, Quality is nothing but data integrity. Under the name of data integrity, regulators are testing our medicines and we have to pass this test. Quality is something we are accepted nationally and internationally, actually by testing and also by perception. India has come a long way to gain the acceptance from all over the world for our medical products.

IDMA since its inception in 1961 has been a great player in ensuring this accessibility. If we look at the structure of Indian Industry, we have a mix of companies - those we used to call multinationals, which were the members of OPPI then the MSME then our Indian companies our APIs. Multinationals have also done a great service by bringing new molecules in our country, new therapy in our country. This has become possible for others to make the generic version of it and to make it easily accessible. They have significantly contributed to the quality of products. Through the mix of these companies, the Indian multinationals arose. And this ecosystem we need to maintain, everybody in this ecosystem is needed. When we work together we will really make such an ecosystem which will make a real difference to the world.

Start-up India which involves innovation, is just picking up. That is the area which we need to work very hard. Skill India has to be very precise, small or big courses which will make people research-ready, industry-ready, quality assurance-ready and Pharmacolovigilance-ready. People need training and we need such skill-India trainings. If we talk about Digital India, we are diverse and our activities are also diverse. This digital India will bring transparency and make 'Transparent India' and it will prove our integrity.

IDMA working through its main office and its eight Boards has been quite successful in bringing out these issues and also taking along with some of the issues with OPPI and IPA has been quite successful. If we keep consulting together we can take up the challenge which we are facing due to reliance on China and through this India will become self-reliant.

If we work together we can assure that all concerns of the pharma industry will be taken care of. If we work together and keeping the vision of our prime minister by keeping a focus on the patient and by keeping access to quality affordable medical products, probably we will achieve our motto and IDMA should strive hard towards this."

Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health and Family Welfare in his address described IDMA as "wonderful, thousand members plus organization, which has been an inspiration since inception in 1961 and has spearheaded as an industry body". He congratulated



IDMA for the completion of the 58th year of existence and partnership in the Nation building. (*Excerpts from his speech*): "In terms of what has been providing as quality medicine, as efficacious medicines, as variably know as Pharmacy of the World. My accolades and Congratulations to the wonderful organization."

The Industry which has today manufacturing capabilities & products of our \$ 37 Bn and out of which almost 50% plus 19 Bn Dollars is the export is something which is of a great credit.

One must live in a present that is here and now. One should not feel bothered about what is past and what holds one's future because that is beyond one's control. But as a country, as an industry body, as a nation, I believe in the need to learn from our experience in past and also we need to have a clear vision for our future so that road map has to be clear & delineated and may be work backwards, so that we actually achieve our objectives are really looking forward.

I am sure with all the inputs we have with so many awards going around people doing so much of excellence, work in individual and as corporate companies, we all be able to hold out a banner of a prominent manufacturing country. Which will supply big time not only to the huge domestic market, but also to the globe in a much larger number than what we are doing today.

The industry has remained resistant despite the economic slowdown and it's proven in these trying difficult years. There is an opportunity they are laying forward in the next few years US patent and Trademark office ensuring that over the 50 Bn worth drugs will go off patent. May be here lies a window of opportunities for us. To ensure that our generics which have proven over the years can be increased big time and the exports, as well as domestic production, can go up substantially.

Ministry of Health & Family welfare and CDSCO prime responsibility is to ensure the smoothness in the quality of drugs often efficacy. Recent amendments in Drugs and Cosmetics Act and Rules, Shri Deepnath Roy Chowdhury has brought out certain very pertinent issues, industry feels need to be worked on, let me ensure that whatever government does & is going to do will be in line within the process, we are trying to ensure. In the last two years, there should not be unpredictability in the actions.

We have noted down a number of points raised by the IDMA President, and we have a copy of Opening Remarks. We are working very closely with a lot of consultations. The last couple of years the Department & CDSCO worked towards building the process of transparency. Dr Somani talked about Digital India which is a big part of the transparency process is going digital. SUGAM is an initiative which has over the last couple of years we are trying to improve upon. Still, lots of work needs to be done. We get regular updates from the industry. We are updating the existing states of SUGAM and to make it a force multiplier. We are working on the portal to ensure things are time-bound and to ensure things are right earnest.

In terms of ease of doing business, a lot of things have been done, the WHO-GMP certificate, its life has been increased from 2 – 3 years. The licensing has been made into perpetuity. The removal of the requirement of NOC from CDSCO port Offices, which has ensured imparting carrying out the general business. New Drugs & Clinical Rules 2019 which came about in March was a major step forward in innovation of trials & for getting new molecules for certain diseases. They are time-bound approaches which are part of this regulation,

In manufacturing, the overall atmosphere & ecosystem of innovation would prevail in the industry. Up-gradation of Schedule M & Marketing Company is responsible for

the drug are issues within the Ministry, we will be holding another round of consultancy with the industry.

I congratulate the incoming President Shri Mahesh Doshi and also wish the outgoing President Shri Deepnath Roy Chowdhury congratulations for having a wonderful tenure as a President, guiding this great organization and hope that we work together as a group to ensure that access to the medicine is so crucial not only to this country but also for the Globe as a whole."



Chief Guest Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers, in his address congratulated IDMA "for completing 58th Year and going from strength to strength over the years is really very big achievement." (Excerpts from his

speech): "IDMA and other organizations have done an excellent job for the country. When there is slow down in other sectors only the pharma sector is growing at the rate of 12-13% and I am very happy to say that exports for the month of November were almost 13% increased. And it's only because of your efforts today India is the Pharmacy of the World.

Some issues are raised by Shri Deepnath Roy Chowdhury. I feel there is a need for a predictable policy and a stable policy and we are working on that. We went on public consultation and we have received many inputs from MSME and we are working on it. We had clubbed together because we wanted to come out with a complete policy, which will be stable and which will be not touched for some time, so that investments can be made accordingly.

The second suggestion we have received on cost price. We have to move from costs approach to market price approach and it should have been done earlier. We have tried to address the distortions and we have increased the price of 21 formulations. We have asked NPPA to look into the matter and certainly, you will get the solutions. We are supposed to provide affordable medicines to the people. Today more than 60% expenditure is on health which is highest in the world. Department of Pharmaceuticals should also have a policy of development of the industry and we are working on this aspect.

In relying upon faster policy we must have the database of all the manufacturing units in India. In certain aspects, we are critically dependent on china for APIs.

We have to come out with the schemes to promote the APIs manufacturing within the country and for that we need database of manufacturing units in India. We have approved six Drugs Parks in the country, Andhra Pradesh, Telangana, Himachal Pradesh, Gujarat, Tamil Nadu and Karnataka. For API investment we have to make an incentive scheme and we have already proposed to the Government and we are working on it. We have also consulted to the industry what kind of incentive is needed. What is the difference between the costs of API manufactured from China. Two years before I was told it will differ by 10-20%. We are doing a survey and if you can provide the data and information we can recommend for approval to appropriate policy can come up with the global standard.

I would like to congratulate each and everyone for getting awards in Research and Patents. But in R&D our concern is that we need to work more on New Drug discovery. We have to work on that and we had asked for the suggestions and inputs from the people. One problem in Indian Pharmaceutical Research is that there are many multiple research Institutes in the country but there is no coordination. So everybody is getting a grant from Central Government, some are getting a grant from the State Government and they are working on a separate manner. There is no focus. We need to improve the Research ecosystem and I would like to share that our Department, CDSCO and Animal husbandry are working together and we are preparing a report that an ecosystem can be prepared and put in the practice and making our timelines, process and transparencies to the international levels.

The third issue we are facing is Industry-Academia interaction, it is already there but we need to do on the lines of USA and Europe in which linkage can be strong and there can be greater involvement of the government promoting and financing the Drugs discovery. This is what we need to improve. Another issue raised was Environment Clearance. It is a problem, especially in API, we have raised this issue with the Ministry of Environment and they have said the issue will be carefully resolved. What we are trying to do is that the Bulk drugs park which is coming in India should be based on plug and play. That means the environment clearance shall be taken care by the State Government and the investor or entrepreneur shall start production, he need not be required to take the clearance from the Central Government.

We have formed a committee to recommend issuing a QR code from one office instead of multiple offices involved in issuing QR codes. As suggested QR codes should be implemented in Exports first. And same QR code shall be referred by the other ministries like Commerce Ministry. In my opinion, we don't require multiple agencies to regulate. Let the regulatory body regulate the industry and pricing issue is against free trade and it should be removed in the long run.

We have formed two consulting forums for an interdepartmental technical committee, which all the different research organizations will make accountable for result-oriented. We have already started a single-window system to avoid multiple authority clearance, The investor shall get all clearance at one window. The single window will solve the issue of such issues. We have already released an advertisement and we are working on the single window system.

There were several Awards distributed during the Celebrations as follows:

IDMA CORPORATE CITIZEN AWARDS 2019

Category: Turnover above ₹500 Crores and	Lupin Human Welfare & Research Foundation
Category: Turnover Less than ₹500 Crores	RPG Life Sciences Ltd

IDMA-INDIAN DRUGS DISTINGUISHED CONTRIBUTION AWARD 2019

Dr N Udupa, Editorial Board, Indian Drugs

IDMA QUALITY EXCELLENCE AWARDS 2018-19

Sr. No.	Member Company Name				
	GOLD AWARDS				
1	Blue Cross Laboratories Ltd, Goa Unit. Category: Formulations Unit - Companies with Total Annual Turnover Above ₹100 Crores				
2	Ind–Swift Limited, Punjab Unit. Category: Formulations Unit - Companies with Total Annual Turnover Above ₹100 Crores				
3	Micro Labs Limited, Sikkim Unit. Category: Formulations Unit - Companies with Total Annual Turnover Above ₹100 Crores				
4	RPG Life Sciences Ltd, Thane Unit. Category: Bulk Drug Unit - Companies with Total Annual Turnover Above ₹100 Crores				
	SILVER AWARDS				
1	Apex Laboratories Pvt Ltd, Chennai Unit. Category: Formulations Unit - Companies with Total Annual Turnover Above ₹100 Crores				
2	Micro Labs Limited, Bangalore Unit. Category: Formulations Unit - Companies with Total Annual Turnover Above ₹100 Crores				
3	Vital Healthcare Pvt Ltd, Nashik Unit. Category: Formulations Unit - Companies with Total Annual Turnover Upto ₹25 Crores				

	BRONZE AWARD				
1	1 Pharma Impex Laboratories Pvt Ltd, Kolkata Unit. Category: Formulations Unit - Companies with Total Annual Turnover Upto ₹100 Crores				
	APPRECIATION AWARD				
1	Twenty First Century Pharmaceuticals Pvt Ltd, Roorkee Unit. Category: Formulations Unit - Companies with Total Annual Turnover Above ₹100 Crores				

IDMA MARGI PATEL-CHOKSI MEMORIAL BEST PATENT AWARDS 2019

Best Biotech Patents Award 2018-19	Granted to M/s Biocon Ltd 33 (18 Patent Families) Patents
Best Pharmaceutical Patents Award 2018-19	Granted to M/s Hetero Drugs Ltd 12 API & 5 Formulations Total 19 Patents
Best API Patents Award 2018- 19	Granted to M/s Emcure Pharmaceutical Ltd 13 APIs Patents & 1 NCE Patent (2 Families)
Best API Process Patents Award 2018-19	Granted to M/s Aurobindo Pharma Ltd 3 API Process Patents
Best Formulation Patents Award 2018-19	Granted to M/s Neon Laboratories Ltd 3 Formulation Patents
API Process Patents Award 2018-19	Granted to M/s RPG Life sciences Ltd 2 API Patents
Formulation Patents Award 2018-19	Granted to M/s Indoco Remedies Ltd 2 Formulation Patents
Patent Appreciation Award 2018-19	Granted to M/s Micro Labs Ltd 1 Process Patent

IDMA-ACG-SCITECH RESEARCH PAPER AWARDS 2019

Review Article	Paper: 'Drug Delivery to Retina: A Review' Authors: Satish Shirolkar and Shelke D A Institute: Department of Pharmaceutics, Dr. D.Y.Patil Institute of Pharmaceutical Sciences and Research, Pimpri, Pune - 411018, Maharashtra, India	
Pharmaceutical Chemistry	Paper: 'Synthesis and evaluation of some newer quinazolinonyl substituted benzoxazepinyl/benzothiazepinyl indoles as potent anticonvulsant agents'.	
	Author: Dr Archana	
	Institute: Medicinal Chemistry Laboratory, Department of Chemistry, Meerut College, Meerut - 250 001, Uttar Pradesh	

Natural Products	Paper: 'Extraction, quantitative determination and spectral identification of Carnosic Acid – a diterpene antioxidant from Rosmarinus officinalis'.
	Authors: Usha Rani N. and Prasad Rao P.T.S.R.K.
	Institute: Department of Freshman Engineering, Prasad V. Potluri Siddhartha Institute of Technology, Vijayawada - 520 007, Andhra Pradesh
Pharmaceutical Analysis	Paper: 'Quantification of Hydrazine Hydrate in Imatinib Mesylate at Genotoxic Level by Chromatographic Method'.
	Authors: Sojitra C., Agarwal S., Dholakia C., Sudhakar P. and Singh K. K.
	Institute/Industry: New Drug Discovery, Zydus Research Centre, Cadila Healthcare Ltd. Ahmdabad, Gujarat
Pharmaceutics	Paper: 'Synergistic Effect of Nigella Oil And Clotrimazole as Ethosomal Gel for Improved Treatment of Fungal Infections'
	Authors: Momin M., Butte K. and D'Souza A.
	Institute: SVKM's Dr Bhanuben Nanavati College of Pharmacy, Mithibai College Campus, V. M. Road, Vile Parle (W), Mumbai – 400 056, Maharashtra
Pharmacology	Paper: 'Synthesis and Biological Evaluation of 2-Phenylpyrido [2,3-D] Pyrimidine Derivatives as Cyclin-Dependent Kinase (CDK) Inhibitors'
	Authors: Panchabhai V. B., Ingole P G and Butle S R
	School of Pharmacy, SRTMU Campus, Vishnupuri, Nanded, Maharashtra

IDMA J B MODY BEST STUDENTS AWARDS 2018 AND 2019

There were 41 students (18 in 2018 and 23 in 2019) from 20 Universities/Institutions received the IDMA JB Mody Best Students Awards from various universities all over India. They were presented with a Cash Award, a certificate and a memento.

- 1. **Mr Lohith K. C.**, B Pharm 2019, Acharya & BM Reddy College of Pharmacy, RGUHS University.
- 2. **Ms Jojiya Grace George**, B Pharm 2018, Amrita School of Pharmacy, Kochi.
- 3. **Ms Meghna M**, B Pharm 2019, Amrita School of Pharmacy, Kochi.
- Ms Pokar Dhruvisha Jayesh, B Pharm 2018, Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai.
- 5. **Ms Pallavi Singh**, B Pharm 2019, Bharati Vidyapeeth's College of Pharmacy, Navi Mumbai.
- 6. **Mr Nachiket Dandekar**, B Pharm 2018, Bombay College of Pharmacy, Mumbai.

- 7. **Ms Aditi R Bhat**, B Pharm 2019, Bombay College of Pharmacy, Mumbai.
- 8. **Ms Priti Ramakant Gupta**, B Pharm 2019, C U Shah College of Pharmacy, Mumbai.
- 9. **Mr Shubham Gupta,** B Pharm 2018, Devi Ahilya Vishwavidyalaya, Indore.
- Mr Anuj Khandelwal, B Pharm 2019, Devi Ahilya Vishwavidyalaya, Indore.
- 11. **Mr Neelabh Kashyap**, B Pharm 2018, Dibrugarh University.
- 12. **Ms. Nikita Dey**, B. Pharm 2019, Dibrugarh University.
- Ms Nadar Divya Pauldurai, B Pharm 2018, H K College of Pharmacy, Mumbai.
- Mr Patel Zeeshan Feroz Rehana, B Pharm 2019,
 H K College of Pharmacy, Mumbai.

- 15. **Ms. Juhi Viraj Salgaonkar**, B Tech (Pharm) 2018, Institute of Chemical Technology, Mumbai.
- 16. Ms Amruta A Dandekar, B Tech (Pharm) 2019. Institute of Chemical Technology, Mumbai.
- 17. **Ms Neha Ramesh Pai**, B Pharm 2018, Institute of Chemical Technology, Mumbai.
- 18. **Mr Purav Jignesh Shah**, B Pharm 2019, Institute of Chemical Technology, Mumbai.
- 19. **Mr Saravanan B**, B Pharm 2018, JSS College of Pharmacy, Ooty.
- 20. **Ms Anusha S,** B Pharm 2019, JSS College of Pharmacy, Ooty.
- 21. **Ms Sharada Sairam**, B Pharm 2019, JSS College of Pharmacy, Ooty.
- 22. **Ms. Srilaxmi G Rao**, B. Pharm 2018, Manipal College of Pharmaceutical Sciences, Manipal.
- 23. **Ms Hawa Bachoo Hashim**, B Pharm 2019, Manipal College of Pharmaceutical Sciences, Manipal.
- 24. **Ms Keerthana**, B Pharm 2019, Manipal College of Pharmaceutical Sciences, Manipal.
- 25. **Ms Tanvi Kamat**, B. Pharm 2018, MET Institute of Pharmacy, Mumbai.
- 26. **Ms Shruti Sawant**, B Pharm 2019, MET Institute of Pharmacy, Mumbai.
- 27. **Mr Burhanuddin Idris Kagalwala**, B Pharm 2018, Oriental College of Pharmacy, Navi Mumbai.
- 28. **Ms Bangar Pratiksha Sitaram**, B Pharm 2018, Oriental College of Pharmacy, Navi Mumbai.
- 29. **Mr Aditya Ajit Singh**, B Pharm 2019, Oriental College of Pharmacy, Navi Mumbai.
- 30. **Ms Mansi Damani**, B Pharm 2018, Principal K M Kundnani College of Pharmacy, Mumbai.
- 31. **Mr Mayur Jeevan Bansari**, B Pharm 2019, Principal K M Kundnani College of Pharmacy, Mumbai.
- 32. **Ms Jyotshnarani Sahoo**, B Pharm 2018, Siksha O Anusandhan University, Odisha,
- 33. **Mr Sangbit Paul**, B Pharm 2019, Siksha O Anusandhan University, Odisha.

- 34. **Ms Swapnali Sanjay Abhale**, B Pharm 2019, S.N.D.T. Women's University.
- 35. **Ms Richa Pravin Rajput**, B Pharm 2018, SVKM'S NMIMS, School of Pharmacy & Technology Management, Mumbai.
- 36. **Ms Janvhi Machhar**, B Pharm 2019, SVKM'S NMIMS, School of Pharmacy & Technology Management, Mumbai.
- 37. **Ms Kumari Pragya**, B Pharm 2018, SVKM'S Dr Bhanuben Nanavati College of Pharmacy, Mumbai.
- 38. **Ms Amrita Avinash Date**, B Pharm 2019, SVKM's Dr Bhanuben Nanavati College of Pharmacy, Mumbai.
- 39. **Ms Aakriti Sethi**, B Pharm 2018, University Institute of Pharmaceutical Sciences, Panjab University.
- 40. **Ms Pariksha Oberoi**, B Pharm 2019, University Institute of Pharmaceutical Sciences, Panjab University.
- 41. **Ms Shreeya Jadhav**, B Pharm 2019, Vivekanand Education Society's College of Pharmacy, Mumbai.



The celebrations ended with a Vote of Thanks proposed by Mr Bharat Shah, Hon General Secretary. He thanked Chief Guest Dr P D Vaghela for his gracious presence at the Annual Day and for his very informative and reassuring address. (Excerpts from Mr Bharat Shah's Vote of Thanks is published in the following pages):

Opening Remarks by Shri Daara B Patel, Secretary General



It gives me great pleasure to welcome our Hon'ble Chief Guest Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Guests of Honour Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health and Family Welfare and Dr V G Somani, Drugs Controller General of India.

National President Shri Deepnath Roy Chowdhury, Incoming National President Shri Mahesh Doshi, Distinguished Guests, our Presidents who have contributed immensely for the growth of IDMA, Captains of Industry and Fellow Members of IDMA, Distinguished winners of various IDMA Awards, Members of the Press, Ladies and Gentlemen;

We would like to welcome our Dignitaries on the Dias with Flowers.

Wishing you all a very happy, Prosperous and a smooth 2020 ahead!! A very warm Welcome to all of you to the 58th IDMA Annual Day Celebrations. We are all in for a very interesting and enjoyable evening. I would like to welcome dignitaries in the audience.

There are many awards to be given away in recognition of various achievements in manufacturing, in patents, in research, in education, in CSR etc that we all can be proud of.

Though this may be a bit taxing, all speakers have graciously agreed to support us by adhering to the time limit and we seek your patience and co-operation to make this evening a truly memorable one! From our side, we promise to make this meeting very informative, crisp and interesting.

Today we have Good News and more Good News to share with you.

- ✓ IDMA is 1000 Plus Members strong and still growing.
- ✓ IDMA, with Secretariat Head Office in Mumbai and Branch Office in Delhi, has State Boards covering Gujarat, Himachal Pradesh, Uttarakhand, Tamil Nadu, Puducherry, Kerala, Haryana, Punjab, Madhya

- Pradesh, Telengana, Karnataka and West Bengal.
- IDMA takes its CSR duties quite earnestly and has been bestowed with the **first-ever Indian Pharma Swachhta Champion Award** by the Hon'ble Minister for Chemicals and Fertilisers Shri D V Sadananda Gowda and Hon'ble Minister of State Shri Mansukh L Mandaviya at the 4th India Pharma & Medical Device Awards held last year. IDMA won the Award among other participants for the cleaning up activities by IDMA Secretariat at the BYL Nair Charitable Hospital, Mumbai, a Government run institution.
- ✓ IDMA responded to an urgent S O S from Dr V G Somani, DCG(I) seeking IDMA's support by way of medicines for flood affected places in Maharashtra and initiated immediate action and supplied medicines to designated places as requested by Government. IDMA also responded to appeals from Kerala Government for supply of medicines for the flood affected people.
- ✓ IDMA is the only Association that publishes a weekly 'IDMA Bulletin' to keep Members and readers informed – this has been carried out for the last 51 years without missing a single issue, come rain, thunder, storm, riots or Bandhs! We also publish a monthly Scientific and Technical Journal 'Indian Drugs' for the past 57 years.
- ✓ IDMA and IDMA State Boards actively conduct Training Seminars, Workshops and Conferences throughout the year to keep our Members up to date on the regulatory requirements, Technology updates etc., DoP and CDSCO have partnered with us for a number of Training Programmes.
- ✓ IDMA represents and has Members from all sectors of the industry – Large, Medium, Small, Micro, APIs, Formulations, Nutraceuticals, biotec, allied industries and service providers — thus making us truly a representative National Association.
- ✓ We work closely with other like-minded Associations like BDMAI, OPPI, IPA etc.
- We support the API industry and want to work closely with the Government to bring it back to its past glory.
- Our theme for this year is well thought out: 'Indian
 APIs & Pharmaceuticals for Global Healthcare'.

We need urgent Government Policy support for the following

- ✓ Revival of the API Industry
- ✓ Environment/Pollution issues
- ✓ Price Controls
- ✓ Frequent changes in Notifications

We are sure of receiving the necessary impetus and support from the Government.

Thank you once again for joining us in this Celebrations and a warm welcome once again.

I would now request our National President Shri Deepnath Roy Chowdhury to kindly deliver his Presidential Address.

• • •

Address by Shri Deepnath Roy Chowdhury, National President



WELCOME:

Chief Guest Dr P D Vaghela, Secretary, DoP, Guest of Honour Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health & Family Welfare, Guest of Honour Dr V G Somani, Drugs Controller General (India), Dr S Eswara Reddy, Joint Drugs

Controller (India), Mr Uday Bhaskar, DG, Pharmexcil, Mr Sudarshan Jain, Secretary General of Indian Pharmaceutical Alliance, Mr A Vaidheesh, President, OPPI, Mr Bharat Shah, Hon General Secretary, IDMA, Mr Daara Patel, Secretary-General, IDMA, Distinguished Guests, Past Presidents, Captains of Industry, Fellow Members of IDMA, Distinguished Winners of various IDMA awards, Members of the Press, Ladies and Gentlemen;

I have great pleasure in welcoming you to the 58th IDMA Annual Day Celebrations.

INTRODUCTION:

As the premier national Association of Pharma manufacturers, IDMA has been in the forefront of making our Nation self-sufficient in the manufacturing of drugs and pharmaceuticals and is appropriately known as the "Voice of the National Sector". IDMA truly represents the entire spectrum of the Pharma Industry be it Formulations, APIs or Exports in the small, medium & large sectors.

Three years back I took over as the National President of IDMA with a mission to serve you and the Indian Pharma Industry at large. I have been privileged & honoured to lead this 58 year old great organization. I am humbled by the trust and confidence you have reposed in me and my team of office bearers during the last 3 years.

Needless to say during this journey I have received unstinted support from all our Past Presidents, members of various StateBoards, Chairmen & Members of various committees and the Secretariat led by Secretary General Mr Daara B Patel ably assisted by Deputy Secretary General Mr T R. Gopalakrishnan and Executive Director Mr Ashok Kumar Madan.

It has been a pleasure and an enriching experience to function under the loving but watchful eyes of the Past Presidents. May you continue to inspire future leaders of IDMA.

IDMA is respected by the Authorities & Policy makers because of our knowledge and credibility. That has been possible because our Committees are chaired by persons like Dr Gopakumar Nair, Yogin Majmudar, S M Mudda, Dr George Patani, B G Barve, Dr R K Sanghavi, Amit Rangnekar, M Devesh and others who are extremely resourceful, dedicated & most importantly passionate about protecting the Industry's rightful interest. We also have young, dynamic, successful & effective leaders in members like Viranchi Shah, George Patani, Jayaseelan who I am sure will take IDMA to greater heights in the future.

I am confident that incoming President Mahesh Doshi & his team will carry forward the rich legacy of this remarkable Institution.

RECENT DEVELOPMENTS:

Allow me to briefly touch upon <u>a few important</u> <u>developments</u>.

DoH & DCG(I):

As far as the Departmentof Health & Family Welfare and the DCG(I) are concerned we are in regular touch and I must acknowledge that our representations are accorded due importance. Since Dr Mandeep K Bhandari, Joint Secretary, Health and DCG(I) Dr V G Somani are here I take this opportunity to touch upon a few issues which need to be resolved.

- * We thank the Health Ministry and the DCG(I) for responding positively to our long standing request for extending the validity of CoPP from 2 to 3 years.
- * We appreciate the Government's initiative in extending implementation of amendments to labeling rules on voluntary basis till 31st March'19.
- * We thank DCG(I) Dr V G Somani for responding to our request and taking the initiative to conduct seminars across the country to resolve SUGAM related issues.
- * As far as retaining brand name in case of change of API in formulation is concerned, we have represented that a prefix or suffix to an existing brand name be allowed. I am sure DCG(I) will find merit in our proposal and respond appropriately.
- * As far as the FDC issues are concerned the Ministry and DCG(I) are taking decisive steps and we assure you of our fullest cooperation to resolve the matter expeditiously.
- * The proposal to revise Schedule-M is far reaching and requires wide consultation. While the Schedule-M is based on WHO guidelines, unlike a guideline it will be a law and even bonafide & unintentional non-compliance of any provision will be considered as an offence. We will request the decision makers present here to kindly consider the global practice of providing mandatory regulations and guidelines separately.

We have made a detailed submission to the appropriate authorities and would look forward to a consultative process in finalizing the proposed Schedule-M.

- * We have made a request for reconsideration for the fees of ₹15000/- to be paid for FDCs which have been approved prior to the date of the New Drugs and Clinical Trial Rules 2019 notification.
- * Since all the senior officials are here we would like to bring it to your notice that the Drugs & Cosmetics Act & Rules that regulates the Industry, needs a

revamp in terms of penalty and punishment for offences which are not major in nature. Every offence is viewed as a criminal act and entrepreneurs have to undergo tremendous stress and harassment for committing even minor violations. It indeed calls for serious introspection.

DoP:

- * We are thankful to the DoP for introducing the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS) and also for including the SSI sector in addition to medium enterprises. We are thankful for having the National President of IDMA as a member of the committee set up in this regard. We have made a few suggestions (Increasing Ioan amount to ₹10.00 crores/WHO compliance time to be extended to 3 years / Delinking Export condition). We would request Secretary DoP to kindly expedite finalization of the disbursal mechanism and the Disbursing Authority so that the benefits of PTUAS could reach the target audience at the earliest.
- * A major concern of the Government in recent times has been the critical dependence on API imports from China. After several meetings with the Government Authorities we have made a few recommendations. We have discussed with Secretary, DoP and explained the environmental issues that are hindering the development of the API sector. We are thankful to him for taking up our concerns in right earnest.

Promoting API manufacturing in India is indeed a serious matter concerning national health security and we all must marshal our resources to address the issue.

POLICY (NLEM & DPCO):

A few words about the proposed Pricing Policy:

As far as NLEM revision is concerned our view is that;

- * 'Essentiality' should be the criterion for inclusion and not the market size, sales data or span of control.
- Only specific strength & dosages should be included in the NLEM.

We understand that the Government is working on a new Policy.

- * We have requested DoP & NPPA to keep less than ₹5/- per unit products out of price control.
- * We have also requested that incremental innovation be given due recognition for the purpose of price determination.
- * It has been our long standing request that revised price is implemented prospectively from the next batch. This is aimed at simplification and will definitely ensure better compliance without giving rise to unnecessary disputes.
- * We are thankful for the recent price increase granted to certain formulations under Para 19 of DPCO 2013. We would request that such revision be extended to other formulations also that are severely affected.

AUTHENTICATION (DoP & DoH):

- Varied directions from different authorities is causing confusion and uncertainty.
- * We would request DoP, DoH & DCG(I) to please ensure a single direction, a simple consolidated guideline.
- * We would also request that the chosen authentication mechanism be proposed for the domestic market only after the same has been extensively used in exports for a few years.

These are some of the important points that I wanted to discuss with the Honourable Guests on & off the dais and the audience. Print copies of my detailed report covering all relevant issues will be circulated to you shortly.

CONCLUSION:

I would conclude by saying that;

The Indian Pharmaceutical Industry has done the country proud over the years. It is rightly described as the pharmacy of the world and the goal is to take it to the next level. At this juncture, there is a need for stronger collaboration between Industry, Government & regulatory agencies. We will continue to work with the Government and Regulators to find the right balance between protecting innovation and providing access to high-quality, affordable medication.

IDMA will continue to pursue its unflinching commitment to values and ensure that business & ethics always go together.

We reiterate that we are fully geared to support the Government in achieving its objective of Quality-Affordability-Accessibility. Sir, with all of you by our side the IPI can indeed conquer new horizons.

The world has recognized India as the preferred supplier of safe efficacious quality generics and increasingly looks towards India to provide quality affordable APIs and Pharmaceutical formulations. Hence the incoming team has chosen the theme: 'Indian APIs & Formulations for Global Healthcare'.

It is my pleasure to acknowledge the support and co-operation received from Hon'ble Ministers, Senior Officials, Government bodies, our sister Associations and well-wishers.

When this journey started in January'17 I had concluded my address with a quote from one of the greatest sons of India Gurudev Tagore "I slept and dreamt that life was joy, I awoke and saw that life was service, I acted and behold, service was joy". The primary responsibility of the President & Team IDMA is indeed to render service to its members and to the Nation at large.

To summarize the takeaway from this wonderful, challenging but fulfilling 3 year journey I would once again like to quote the great Tagore "I have received much more from the people than I have given them".

Ladies & Gentlemen I once again welcome you all to this grand evening and look forward to interacting with you.

May all of you have a Happy, Healthy & Happening 2020.

Thank you all for your support and your affection.

May God bless us all.

• • •

Address by Shri Mahesh Doshi, Incoming National President



Hon'ble Chief Guest Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Guests of Honour Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health and Family Welfare and Dr Venugopal Somani, Drugs Controller General of India.

Shri Deepnath Roy Chowdhury, National President, IDMA, Shri Daara Patel, Secretary- General, IDMA, Distinguished Guests, Past Presidents, Captains of Industry and Fellow Members of IDMA, Distinguished winners of various IDMA Awards, Members of the Press, Ladies and Gentlemen;

I am indeed grateful to all our Past Presidents, Seniors and Members of the Executive Committee of IDMA for having bestowed confidence in me by electing me as the first-ever Senior Vice-President of this great Association, the apex body of Pharmaceuticals and API Manufacturers This position, as the *de facto* President-elect enabled me to work alongside the National President Shri Deepnath Roy Chowdhury in carrying out his responsibilities over the last many months. I am now honoured to have been elected as the National President at the Annual General Meeting of the Association held earlier today. I accept this position in all humility.

I have been associated with IDMA for over three decades and have been entrusted with various responsibilities as Treasurer, Honorary Secretary and Vice President etc. Every President who preceded me has contributed his time and efforts towards IDMA's success; and having worked with most Past Presidents, it has been a good learning experience for me and I hope that I justify the faith reposed in me by our Members. I promise to do my best not only in keeping the flag of IDMA flying high, but also reaching greater heights. At this time, I deeply miss the presence of my late Mentors Shri D B Mody and Shri N I Gandhi, who guided me and supported me in carrying out my various responsibilities as IDMA Office-Bearer all these years. In fact, they were more confident than me in my ability to lead the Association. I will try my best to live up to their Confidence and Vision.

Today, we are 1000 plus Members strong and I hope that we manage to get many more Members to join the IDMA family in the next couple of years. We have a very active and vibrant Secretariat, headed by Shri Daara Patel, Secretary-General. We have 20 Committees with dedicated Chairmen and Vice-Chairmen and supportive Members, as also eight State Boards all over India in Pharma-centric cities. I would like to continue with the objectives laid out by my predecessors in providing greater thrust on training programmes and seminars for our SME members jointly with CDSCO and Department of Pharmaceuticals.

It will be my earnest desire to support and guide our members, especially our SME Members, in meeting the regulatory requirements of not only our country but also other major markets like US, Europe, Japan etc. As mentioned by Deepnathji in his Presidential address, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), if properly implemented, would ensure that all our Small and Medium sector Members, who make up most of our Membership, upgrade to WHO GMP and those who are already WHO GMP complaint, upgrade to US FDA, EDQM and other international compliances. Today, there are over 2000 WHO GMP approved units. With proper guidance and support by DoP, CDSCO, DCG(I) etc it is very possible that this number is doubled to 4000 by next year.

We have two major objectives to meet:

- To ensure accessibility of our affordable quality medicines to the vast population of this country and also globally;
- 2. To ensure that our API Industry is supported to achieve self-sufficiency in producing all APIs required to accomplish the first objective.

I am sure that, in collaboration with other industry-Associations such as Pharmexcil, BDMAI, OPPI, IPA, FOPE etc., we will surely achieve these objectives.

My predecessors, Veerramaniji and Deepnathji had their hands full in supporting and keeping our bulk dung industry afloat against the onslaught of imports of APIs and intermediates from China. Till about a decade ago, China was trying to catch up with us in APIs. Today, with their Government's unstinted support, they have moved

far ahead and we are trying to catch up with them in APIs. Though we are still dependent on China to a large extent on intermediates and APIs, with Government's support, we can go a long way towards self-sufficiency very soon.

We had many interactions with various Government Ministries and Departments, as also submissions for addressing the need for flexibility in clearances and approvals for the bulk drug industry, spearheaded by Shri Yogin Majmudar, Past President and Chairman of IDMA Bulk Drugs Committee. We are happy to note that Government is now moving towards ease of doing business measures such as approval of product change without having to seek fresh Environment clearances from State Boards where there is no increase in Pollution load.

We support the Government's objectives and mission of healthcare for all people, especially the poor through Ayushman Bharat. The industry is fully geared up to support the Government in ensuring that such noble objectives are achieved. The primary objective of every government is to ensure that medicines reach the poorest of the poor in the rural area. We once again reiterate that

the industry is fully geared up to support the Government in ensuring that this objective is achieved.

I would like to form a Think Tank of our Office-Bearers and Senior Members to give proper guidance and direction to IDMA's goals and objectives in supporting the Indian Pharma Industry in making it more efficient and more competent than it already is, in the years to come. In this regard, I look forward to the support of Dr George Patani, Shri Bharat Shah, Shri B G Barve, Dr Viranchi Shah, just to name a few.

The Indian Pharmaceutical Industry has come a long way in the last few decades and now supplies safe and affordable quality medicines, consistently, to India and all the countries globally. The public and the consumers need to appreciate and be proud that we play a significant part in protecting public health, not only in India but all over the Globe. Our theme this year very aptly reflects this: 'Indian APIs & Pharmaceuticals for Global Healthcare'.

I wish you all a very Happy, Successful and Productive year 2020. Thank You.

• • •

Vote of Thanks by Shri Bharat Shah, Hon General Secretary



I am privileged and glad to propose a vote of thanks on behalf of IDMA to the worthy Dignitaries on the Dais, Past Presidents, Distinguished Guests, Invitees, Award Winners and the members in the audience.

Our sincere thanks to Chief Guest Dr P D Vaghela, IAS,

Secretary, Department of Pharmaceuticals, Government of India, for his gracious presence at our Annual Day and for his very informative and reassuring address. We are thankful to you Sir, for your words of wisdom and encouragement. We look forward to working closely with you.

Our sincere thanks to Guest of Honour Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health & Family Welfare, for his thought provoking address and also for showing the way forward for the development and growth of the Indian Pharma Industry.

Our sincere thanks to Guest of Honour Dr Venugopal Somani, Drugs Controller General of India for his initiatives and problem solving attitude. We also appreciate the efforts of the DCG(I) to resolve the problems of the industry in uploading data on SUGAM portal and other e-governance sites.

Our sincere thanks to outgoing National President Shri Deepnath Roy Chowdhury for his well abridged and detailed report on IDMA's challenges and achievements and for having steered IDMA very ably in the last three years. Sir, it has been our proud privilege to be working with you.

Our sincere thanks to incoming National President Shri Mahesh Doshi for his excellent response and presenting his Plans and Policies for IDMA. We wish you all the best for your tenure as our National President. We are confident that you will travel that extra mile to ensure that, in collaboration with Government, the issues and hurdles of the industry are addressed for speedy resolution.

Dr S Eswara Reddy, Joint DCG(I), Dr Rubina Bose, Deputy DC(I), West Zone and Dr P B N Prasad, Deputy DC(I) West Zone and their officers for their support, co-operation and guidance.

Our sincere thanks to Smt Pallavi Darade, Commissioner FDA, Maharashtra and also the Joint Commissioners and Assistant Commissioners for their support and guidance.

Our sincere thanks and congratulations to all the participants as well as the Winners of the following Awards:

- IDMA Margi Patel-Choksi Memorial Best Patent Awards.
- IDMA Corporate Citizen Awards
- IDMA Quality Excellence Awards
- IDMA ACG SciTech Research Paper Awards

Well Done, all of You!

And to the J B Mody Best Student Award Winners, we wish you all a bright future in the service of the Industry and our Nation.

Our sincere thanks to the captains of the industry, members of our Executive Committee, Past Presidents,

Chairmen of various Committees, our Consultants & our Advisors for their continued support and involvement.

Our sincere thanks to Mr Annaswamy Vaidheesh, President of OPPI, Mr Sudarshan Jain, Secretary-General of IPA for their support and for working closely with us on important issues. We also thank Heads, Office-bearers and Staff of Pharmexcil, IPA (Alliance), OPPI, FOPE, CIPI, BDMA and IPA. We are also thankful to Shri J S Shinde, Chairman-cum-Managing Director of AIOCD Ltd.

Our thanks to the Management and staff of Hotel St Regis for all their co-operation and hospitality.

Our thanks are also due to the members of the press for their continued support and for covering today's event.

We also thank the IDMA staff in Mumbai as well as in Delhi for their untiring efforts and contributing to the success of IDMA. Special thanks to our dynamic Secretary-General, Shri Daara B Patel.

Special thanks to AIOCD Pharmasofttech AWACS Pvt Ltd, Fourrts (India) Laboratories Pvt Limited, Micro Labs Ltd, USV Private Ltd and Detox Group, for their generous support in organizing the Annual Day Celebrations and hugely contributing to its success.

A very big thanks to our members and specially members of various State Boards for your support and presence today, for making the IDMA 58th Annual Day Celebrations a truly memorable event. Please join us for Dinner. Thank you.





For Advertising in the Classified Columns and also for series advertisements please contact: Mr Chettiar (+9820629907) Publications Department


IDMA BULLETIN

Tel.: 022 - 2494 4624 / 2497 4308 / Fax: 022 - 2495 0723/ E-mail: mail_idma@idmaindia.com, Website: www.idma-assn.org, www.indiandrugsonline.org

Glimpses of 58th IDMA Annual General Meeting (AGM) 2020



58th IDMA AGM in progress on Saturday, 18th January 2020 at Hotel St Regis, Mumbai. On the dais (from Left to Right) Shri Asheesh Roy, Vice-President (Eastern Region), Shri T Ravichandiran, Vice-President (Southern Region), Shri S V Veerramani, Immediate Past National President, Shri Mahesh H Doshi, Senior Vice-President, Shri Deepnath Roy Chowdhury, National President, Shri Daara B Patel, Secretary General, Shri Bharat Shah, Hon General Secretary and Dr George Patani, Hon Treasurer, IDMA.



Shri Deepnath Roy Chowdhury, National President addressing the Members.



Shri Mahesh H Doshi, Incoming National President addressing the Members.



Incoming National President being felicitated with a flower bouquet by National President Shri Deepnath Roy Chowdhury at 58th IDMA AGM held on 18th January 2020 at Mumbai.

Glimpses of IDMA 58th Annual Day Celebrations 2020



IDMA 58th Annual Day Celebrations 2020 being inaugurated with ceremonious lighting of the Traditional Lamp by Chief Guest Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers accompanied with Guest of Honour Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health & Family Welfare, Dr V G Somani, Drugs Controller General (India), Dr S Eswara Reddy, Joint Drugs Controller (India), CDSCO, Shri Deepnath Roy Chowdhury, National President, Shri Mahesh H Doshi, Incoming National President and Shri Bharat Shah, Hon General Secretary, IDMA.

Glimpses of 58th IDMA Annual Day Celebrations 2020



Shri Daara B Patel delivering the Welcome Address and Opening Remarks.



Shri Deepnath Roy Chowdhury, National President, IDMA felicitating the Chief Guest Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers.



Shri Deepnath Roy Chowdhury accompanied by Mr Mahesh Doshi felicitating the Guest of Honour Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health & Family Welfare.



Shri Deepnath Roy Chowdhury accompanied by Mr Mahesh Doshi felicitating the Guest of Honour Shri Dr V G Somani, Drugs Controller General (India), CDSCO.



Shri Deepnath Roy Chowdhury accompanied by Dr V G. Somani, Drugs Controller General (India) and Mr Mahesh Doshi felicitating Dr S Eswara Reddy, Joint Drugs Controller (India), CDSCO.



Mrs Radha Veerramani, Director, Fourrts (India) Laboratories Private Limited, felicitating Dr Rubina Bose, Dy Drugs Controller (India), CDSCO West Zone.



Shri B N Singh, Past President, IDMA and Executive Chairman, Alkem Laboratories Ltd felicitating Dr P B N Prasad, Dy Drugs Controller (India), CDSCO West Zone.



Shri Deepnath Roy Chowdhury delivering the Presidential Address at 58th IDMA Annual Day Celebrations 2020.



Shri Mahesh Doshi, Incoming National President addressing the august gathering.



Guest of Honour Dr V G Somani, Drugs Controller General (India) delivering his address.



Dr V G Somani being felicitated with a memento by Shri Deepnath Roy Chowdhury accompanied with other diginitaries on the dais.



Dr Mandeep K Bhandari, IAS, Joint Secretary, Ministry of Health and Family Welfare addressing the participants.



Dr Mandeep K Bhandari being felicitated by presenting a memento by Shri Deepnath Roy Chowdhury accompanied with Shri Mahesh Doshi.




Chief Guest Dr P D Vaghela, IAS, Secretary, Department of Pharmaceuticals, Ministry of Chemicals & Fertilizers delivering his address.



The Chief Guest Dr P D Vaghela, IAS being felicitated with a memento by Shri Deepnath Roy Chowdhury and other diginitaries on the dais.



Audience view.



58th IDMA Annual Publication 2020 released.

IDMA Award Presentations (DMA Corporate Citizen Awards 2019)



IDMA Corporate Citizen Award 2019 (Category <500 Crores) presented to M/s. RPG Life Sciences Ltd (Mr Yugal Sikri and his Team received the Award).

CHEF CHART ON P O VACHELLA, IAB Recretary, Report out of Phermac Autor Recretary, Separation of Security of Committee of Security of Committee

IDMA Corporate Citizen Award 2019 (Category >500 Crores) presented to M/s Lupin Human Welfare & Research Foundation. (Mr C V Venkataraman, Director – Corporate Services and Mr Ravi Deshpande, Chief Programme Manager received the Award).

Indian Drugs Contribution Award 2019



IDMA – Indian Drugs Distinguished Contribution Award 2019 being presented to Dr N Udupa, Editorial Board, Indian Drugs by the Chief Guest Dr P D Vaghela, IAS accompanied by Guests of Honour Dr Mandeep Bhandari, IAS, Dr V G Somani and Shri Deepnath Roy Chowdhury.



IDMA Quality Excellence Award 2019 (Gold Award) being presented by the Chief Guest accompanied with all dignitaries on the dais to M/s Blue Cross Laboratories Ltd, Goa Unit, Category: Formulations Unit - Companies with Total Annual Turnover above ₹100 Crores. (Mr B G Barve and his team received the Award).



IDMA Quality Excellence Award 2019 (Gold Award) being presented to M/s Ind -Swift Limited, Punjab Unit, Category: Formulations Unit - Companies with Total Annual Turnover above ₹100 Crores (Award received by Mr Ramesh Souri, President Operations Ind -Swift Limited).



IDMA Quality Excellence Award 2019 (Gold Award) being presented to M/s Micro Labs Limited, Sikkim Unit for the Category of Formulations Unit. (Mr Prakash Mudda, President-Corporate Projects-Operations & Mr Sasikanta Hotta, Vice-President-Technical-Operations received the Award).

IDMA Awards Presentations (Quality Excellence Award 2019)



IDMA Quality Excellence Award 2019 (Gold Award) being presented to M/s RPG Life Sciences Ltd, Thane Unit, Category: Bulk Drug Unit - Companies with Total Annual Turnover above ₹100 Crores. (Mr Yugal Sikri and Team received the Award).



IDMA Quality Excellence Award 2019 (Silver Award) being presented to M/s Apex Laboratories Pvt Ltd., Chennai For the category of Formulations Unit (Mr M Radhakrishnan received the Award).



IDMA Quality Excellence Award 2019 (Silver Award) being presented to M/s Micro Labs Limited, Sikkim Unit for the Category of Formulations Unit. (Mr Prakash Mudda, President - Corporate Projects and Operations and Mr Sasikanta Hotta, Vice President-Technical- Operations, Mr M V Girish, Sr General Manager-Technical-Operations and Mr Patil Ganesh, General Manager-Quality received the Award).



IDMA Quality Excellence Award 2019 (Silver Award) being presented to M/s Vital Healthcare Pvt Ltd, Nashik Unit Category: Formulations Unit - Companies with Total Annual Turnover upto ₹25 Crores. (Dr B K Jogale, Plant Head received the Award).



IDMA Quality Excellence Award 2019 (Bronze Award) being presented to M/s Pharma Impex Laboratories Pvt Ltd, Kolkata unit, Category: Formulations Unit - Companies with Total Annual Turnover upto ₹100 Crores. (Mr Manoj Gupta, MD received the Award).



IDMA Quality Excellence Award 2019 (Appreciation Award) being presented to M/sTwenty First Century Pharmaceuticals Pvt Ltd, Roorkee Unit, Category: Formulations Unit - Companies with Total Annual Turnover above ₹100 Crores.(Ms Rashmi Ranjan Patra, CEO, Mr S Saravanan, General Manager and Mr Ravindrakant, Manager – QA received the Award).

IDMA Awards Presentations (Margi Patel-Choksi Memorial Best Patent Awards 2018-19)



IDMA Margi Patel-Choksi Memorial Best Patent Awards for the year 2018-19 (Best Biotech Patents Award 2018-19) being presented to M/s Biocon Ltd (Dr Monu Kumari and received the award from Chief Guest Dr P D Vaghela, Dr Mandeep K Bhandari and Dr Gopakumar Nair, Past President & Chairman IPR Committee, IDMA).



IDMA Margi Memorial Best Patent Awards for the year 2018-19 (Best Pharmaceutical Patents Award 2018-19) being presented to M/s Hetero Drugs Limited, (Ms Y. Karuna Sree, General Manager, Hetero received the Award).



Best API Patents Award 2018- 19 being presented to M/s Emcure Pharmaceutical Ltd. (Mr Manoj Junnarkar, President–Global Sourcing & Procurement and Mr Chetan Gupta, VP- Corporate Affairs, Dr B Dinesh Kumar, Sr VP - Global IP & Pipeline received the Award).



Best API Process Patents Award 2018-19 being presented to M/s Aurobindo Pharma Ltd. (Dr S D V N Sivaram, Vice President–Intellectual Property received the Award).



Best Formulation Patents Award 2018-19 being presented to M/s Neon Laboratories Limited (Mr Rahul Jain, Director and Dr Neeta Joshi, Manager received the Award).



API Process Patents Award 2018-19 being presented to M/s RPG Life sciences Ltd. (Mr Yugal Sikri and Team received the Award).

IDMA Awards Presentations (Margi Patel-Choksi Memorial Best Patent Awards 2018-19)



Formulation Patents Award 2018-19 being presented to M/s Indoco Remedies Ltd. (Mr Yogesh Bhide, Sr General Manager, Formulation Development and Mr Chetan Gundecha, Manager, IPR received the Award).



Patent Appreciation Award 2018-19 being presented to M/s Micro Labs Limited. (Dr Lukesh Bajaj, GM, API-IP accompanied by Mr Manish Sharma, Manager, API-IP received the Award).

IDMA Awards Presentations (ACG-SciTech Research Paper Awards 2019)



IDMA ACG-SciTech Research Paper Award-2019 for Review Article being presented by the Chief Guest accompanied by Dr Parizad Elchidana, Principal Technical Consultant-Pharma, ACG Worldwide and President-Controlled Release Society-Indian Chapter, Mr Ketan Parmar, Executive Assistant to Chairman, ACG and other dignitaries on the dais (Authors: Mr D A Shelke and Dr S Shirolkar received the Award).



IDMA ACG-SciTech Research Paper Award - 2019 for Pharmaceutical Chemistry being presented. (Author - Dr Archana received the Award).



ACG-SciTech Research Paper Award - 2019 for Natural Products being presented. (Dr Usha Rani N received the Award).



ACG-SciTech Research Paper Award - 2019 for Pharmaceutical Analysis being presented. (Dr Sameer Agarwal received the Award).

IDMA Awards Presentations (ACG-SciTech Research Paper Award 2019)



ACG-SciTech Research Paper Award - 2019 for Pharmaceutics being presented (Dr Munira Momin received the Award).



ACG-SciTech Research Paper Award - 2019 for Pharmacology. (Dr Vivek Panchabhai received the Award)

IDMA J B Mody Best University Student Award 2018 and 2019







IDMA J B Mody Best University Student Award 2018 and 2019 being presented by Chief Guest Dr P D Vaghela, IAS accompanied by other dignitaries on the dais and also the Sponsor of the Award Mr Pranab Mody of J B Chemicals & Pharmaceuticals Ltd

Shri Bharat N Shah, Hon. General Secetray, IDMA delivering the formal Vote of Thanks



IDMA Secretariat Staff along with National President Shri Mahesh H Doshi (The team behind the Grand Success of the Event)